Table 1.
Patients’ characteristics.
| Variables | Study Population | Gemcitabine/Nab-Paclitaxel | FOLFIRINOX | p-Value |
|---|---|---|---|---|
| (n = 147) | (n = 60) | (n = 87) | ||
| Country | <0.001 | |||
| France (n = 4) | 98 (66.7%) | 33 (55%) | 65 (74.7%) | |
| Italy (n = 2) | 37 (25.2%) | 27 (45%) | 10 (11.5%) | |
| Bulgaria (n = 1) | 12 (8.2%) | 0 (0%) | 12 (13.8%) | |
| Age, median (IQR) | 66 (59–72) | 71 (63.8–77) | 63 (56–67.5) | <0.001 |
| Age > 70 years, n (%) | 45 (30.6%) | 33 (55%) | 12 (13.8%) | <0.001 |
| Male sex, n (%) | 83 (56.5%) | 31 (51.7%) | 52 (59.8%) | 0.42 |
| Arterial hypertension, n (%) | 51 (34.7%) | 15 (25%) | 36 (41.4%) | 0.48 |
| Diabetes, n (%) | 49 (33.3%) | 24 (40%) | 25 (28.7%) | 0.21 |
| History of myocardial ischemia, n (%) | 11 (7.5%) | 5 (8.3%) | 6 (6.9%) | 0.2 |
| Performance status, n (%) | ||||
| ECOG 0–1 | 133 (95%) | 50 (87.7%) | 83 (100%) | 0.001 |
| ECOG 0 | 73 (49.7%) | 21 (35%) | 52 (59.8%) | <0.001 |
| ECOG 1 | 60 (40.8%) | 29 (48.3%) | 31 (35.6%) | |
| ECOG 2 | 7 (4.8%) | 7 (11.7%) | 0 (0%) | |
| Missing data | 7 (4.8%) | 3 (5%) | 4 (4.6%) | |
| Tumor location, n (%) | ||||
| Head | 106 (72.1%) | 38 (63.3%) | 68 (78.2%) | 0.11 |
| Body | 34 (23.1%) | 19 (31.7%) | 15 (17.2%) | |
| Tail | 7 (4.8%) | 3 (5%) | 4 (4.6%) | |
| Bilirubin, median (IQR) | 12 (6.5–19) | 8.4 (1.2–14) | 15 (9–20.8) | - |
| Albumin, median (IQR) | 36.6 (33–40) | 36.8 (35–40.9) | 36 (33–39.5) | 0.34 |
| CA19-9, median (IQR) | 127 (36.1–471.2) | 83 (18–403.2) | 172 (57.5–535.6) | 0.07 |
Notes: ECOG: Eastern Cooperative Oncology Group; IQR: interquartile range.